低分子肝素联合拉贝洛尔治疗子痫前期的研究进展
To Evaluate the Efficacy of Low Molecular Weight Heparin Combined with Labetalol in the Treatment of Preeclampsia
DOI: 10.12677/ACM.2024.142577, PDF,   
作者: 夏依达·阿里木, 朱启英, 武建利:新疆医科大学第一附属医院产科,新疆 乌鲁木齐
关键词: 低分子肝素拉贝洛尔子痫前期Low Molecular Weight Heparin Labetalol Preeclampsia
摘要: 子痫前期(preeclampsia, PE)是与妊娠相关的多系统疾病,临床表现为妊娠20周后发生的高血压、蛋白尿、肝肾功能损害和胎盘功能障碍等,严重危及母胎生命安全,是导致我国孕产妇围产期发病率和死亡率增加的主要原因。目前考虑子痫前期不良妊娠结局的发生与妊娠期高凝状态相关,故临床上常使用降压药物及低剂量抗凝药物等进行治疗。本文对低分子肝素联合拉贝洛尔对子痫前期的疗效评价进行综述。
Abstract: Preeclampsia (PE) is a pregnancy-related multisystem disease, characterized by hypertension, proteinuria, liver and kidney dysfunction and placental dysfunction after 20 weeks of gestation, which seriously endanger the life of the mother and fetus and is the main cause of increasing per-inatal morbidity and mortality of pregnant women in China. At present, it is considered that the occurrence of adverse pregnancy outcomes of preeclampsia is related to hypercoagulable state during pregnancy, so antihypertensive drugs and low-dose anticoagulant drugs are used for clinical treatment. This article reviews the efficacy of low molecular weight heparin combined with labetalol in the treatment of preeclampsia.
文章引用:夏依达·阿里木, 朱启英, 武建利. 低分子肝素联合拉贝洛尔治疗子痫前期的研究进展[J]. 临床医学进展, 2024, 14(2): 4172-4176. https://doi.org/10.12677/ACM.2024.142577

参考文献

[1] 李介岩, 侯磊. 低分子肝素预防子痫前期的研究进展[J]. 武警医学, 2023, 34(7): 634-638. [Google Scholar] [CrossRef
[2] 郑路路, 马建彩, 张丽娜, 等. 早发型重度子痫前期患者同型半胱氨酸、血栓弹力图及凝血指标检测的临床意义[J]. 中国计划生育学杂志, 2023, 31(1): 172-176+181. [Google Scholar] [CrossRef
[3] 王淑娟. 低分子肝素联合拉贝洛尔治疗早发型重度子痫前期的临床疗效探讨[J]. 北方药学, 2023, 20(6): 175-177. [Google Scholar] [CrossRef
[4] 罗苗苗, 南延荣, 都燕. 低分子肝素联合硫酸镁及小剂量阿司匹林对早发型重度子痫前期患者子宫动脉血流及NLR、hs-CRP、PCT水平的影响[J]. 临床医学研究与实践, 2023, 8(29): 129-132. [Google Scholar] [CrossRef
[5] 苏淑烺. 低分子肝素联合阿司匹林治疗子痫前期对患者妊娠结局、内皮损伤及胎盘血流灌注的影响[J]. 临床合理用药, 2023, 16(17): 98-101. [Google Scholar] [CrossRef
[6] 王黎. 拉贝洛尔配合低分子肝素对早发型重度子痫前期疗效及母婴结局的影响[J]. 实用妇科内分泌电子杂志, 2023, 10(1): 11-13. [Google Scholar] [CrossRef
[7] 陈茹茹, 罗厚江, 杨军. 低分子量肝素作用机制及临床应用研究进展[J]. 中国现代医生, 2021, 59(6): 182-186.
[8] 张龙华, 周杰. 低分子肝素在妊娠中晚期胎儿生长受限治疗中的作用评价[J]. 实用妇科内分泌电子杂志, 2023, 10(3): 52-54. [Google Scholar] [CrossRef
[9] 孔玲. 拉贝洛尔联合硝苯地平对妊娠期高血压的治疗作用分析[J]. 健康女性, 2021(37): 92.
[10] 杨颖莉, 陈素云. 盐酸拉贝洛尔联合硫酸镁对妊娠期高血压患者的临床作用分析[J]. 中外医疗, 2023, 42(2): 111-115. [Google Scholar] [CrossRef
[11] 张婷婷. 妊高症中硫酸镁拉贝洛尔的药理分析[J]. 中国保健营养, 2020, 30(36): 281.
[12] 马艳艳, 刘春华. 低分子肝素钙联合硫酸镁治疗胎儿生长受限作用机制探讨[J]. 山西医药杂志, 2022, 51(14): 1612-1615. [Google Scholar] [CrossRef
[13] 陈瑞婷. 低分子肝素钠配合拉贝洛尔对妊娠期高血压患者的效果分析[J]. 心血管病防治知识, 2023, 13(2): 10-12. [Google Scholar] [CrossRef
[14] Filipek, A. and Jurewicz, E. (2018) Preeclamp-sia—A Disease of Pregnant Women. Postepy Biochemii, 64, 232-229. [Google Scholar] [CrossRef] [PubMed]
[15] 吴敏, 朱宝菊, 李桃英. 阿司匹林联合低分子肝素对子痫前期合并胎儿生长受限患者的治疗效果[J]. 河南医学研究, 2022, 31(18): 3399-3402.
[16] 莫琳玲, 彭丹, 宋金玲, 等. 低分子肝素与小剂量阿司匹林治疗复发性流产血栓前状态的效果及其免疫调节作用研究[J]. 中国性科学, 2022, 31(9): 81-85. [Google Scholar] [CrossRef
[17] 朱逸星. 拉贝洛尔联合硫酸镁对妊娠期高血压的治疗价值及症状改善作用评价[J]. 心血管病防治知识, 2021, 11(35): 12-14. [Google Scholar] [CrossRef
[18] 梁维经, 刘军现. 拉贝洛尔联合硫酸镁在妊娠期高血压治疗中作用分析[J]. 妇幼护理, 2023, 3(17): 4269-4271, 4278.
[19] 严春红. 拉贝洛尔联合硝苯地平治疗妊娠高血压综合征孕妇的效果及对血压水平的改善作用[J]. 母婴世界, 2023(16): 73-75.
[20] 王桂青, 丁竟成, 熊辉. 拉贝洛尔联合低分子肝素强化方案治疗子痫前期合并胎儿生长受限的疗效观察[J]. 中国合理用药探索, 2023, 20(11): 125-130. [Google Scholar] [CrossRef
[21] 张杰, 李晔. 拉贝洛尔联合低分子肝素治疗早发型重度子痫前期疗效及对尿蛋白水平及母婴结局影响[J]. 中国计划生育学杂志, 2022, 30(6): 1258-1263. [Google Scholar] [CrossRef
[22] Peng, M., Xiao, S., Zhang, W., et al. (2023) Chitosan-Low Molecular Weight Heparin Sodium Nanoparticles Regulate Treg/Th17 Immune Balance and Inflammation at the Maternal-Fetal Interface to Ameliorate Pre-Eclampsia by HB-EGF. Advanced Therapeutics, 6, Article ID: 2300145. [Google Scholar] [CrossRef
[23] Computational and Mathematical Methods in Medicine (2023) Retracted: Efficacy of Low Molecular Heparin on Preeclampsia by Inhibiting Apoptosis of Trophoblasts via the p38MAPK Signaling Pathway. Computational and Mathematical Methods in Medicine, 2023, Article ID: 9794675. [Google Scholar] [CrossRef] [PubMed]
[24] Zheng, L., Xia, B., Yuan, Y., Wang, Y. and Wang, Y. (2022) Low-Molecular-Weight Heparin in Addition to Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 9, Article ID: 1073148. [Google Scholar] [CrossRef] [PubMed]
[25] Scott, G., Gillon, T.E., Pels, A., von Dadelszen, P. and Magee, L.A. (2022) Guidelines-Similarities and Dissimilarities: A Systematic Review of International Clinical Practice Guidelines for Pregnancy Hypertension. American Journal of Obstetrics and Gynecology, 226, S1222-S1236. [Google Scholar] [CrossRef] [PubMed]
[26] Wang, N.N., Feng, C., Sun, M.H. and Pu, Y. (2022) Analysis on Clinical Outcomes of Low-Molecular Weight Heparin Combined with Magnesium Sulfate in Patients with Pre-Eclampsia. Iranian Journal of Public Health, 51, 1067-1075.
[27] 李妍. 拉贝洛尔对重度子痫前期患者血压、24 h尿蛋白水平及分娩结局的影响[J]. 中国现代药物应用, 2023, 17(12): 105-107. [Google Scholar] [CrossRef
[28] 彭丽. 低分子肝素联合拉贝洛尔治疗早发型重度子痫前期的临床研究[J]. 实用中西医结合临床, 2022, 22(23): 38-40+92. [Google Scholar] [CrossRef
[29] 李玉洁, 王彩霞, 许晴, 等. 拉贝洛尔联合低分子肝素治疗早发型子痫前期患者的疗效分析[J]. 现代诊断与治疗, 2022, 33(20): 3039-3042.
[30] 李维真, 陈厚运. 拉贝洛尔联合低分子肝素治疗早发型重度子痫前期患者的临床效果[J]. 中国妇幼保健, 2022, 37(7): 1214-1217. [Google Scholar] [CrossRef